FindTrial
Sign In

AXL1717

DRUG4 trials

Sponsors

Axelar AB, Rush University Medical Center

Conditions

Adenocarcinoma of the LungAnaplastic AstrocytomaAnaplastic EpendymomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaGlioblastomaGliosarcomaNon Small Cell Lung Cancer

Phase 1

A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer
CompletedNCT01062620
Axelar ABSolid Tumors
Start: 2008-04-30Updated: 2011-09-15
A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
CompletedNCT01466647
Axelar ABNon Small Cell Lung Cancer
Start: 2011-01-31End: 2012-09-30Updated: 2012-11-12
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
TerminatedNCT01721577
Rush University Medical CenterAnaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligoastrocytoma +3
Start: 2012-12-31End: 2015-12-31Updated: 2023-05-22

Phase 2

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
CompletedNCT01561456
Axelar ABAdenocarcinoma of the Lung, Non-small-cell Lung Cancer, Squamous Cell Carcinoma
Start: 2011-12-31End: 2013-12-31Updated: 2013-12-05

Related Papers

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial
Acta Oncologica2015-07-1021 citations
Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2014-05-202 citations